Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)

被引：0
作者：
Lorenza, Rimassa [1 ]
Silvia, Bozzarelli [1 ]
Stefano, Cordio [2 ]
Filippo, Pietrantonio [3 ]
Laura, Toppo [4 ]
Sara, Lonardi [5 ]
Alberto, Zaniboni [6 ]
Roberto, Bordonaro [7 ]
Maria, Di Bartolomeo [8 ]
Wanda, Liguigli [4 ]
Vittorina, Zagonel [5 ]
Chiara, Tronconi Maria [1 ]
Luca, Di Tommaso [9 ]
Laura, Giordano [1 ]
Armando, Santoro [1 ]
机构：
[1] Ist Clin Humanitas IRCCS, Humanitas Canc Ctr, Rozzano, Italy
[2] Garibaldi Nesima Hosp, Dept Oncol, Catania, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] Ist Ospitalieri Cremona, Struttura Complessa Oncol, Cremona, Italy
[5] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy
[6] Fdn Poliambulanza, Brescia, Italy
[7] Osped Garibaldi, Unita Oncol Med, Catania, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Dept Oncol, Milan, Italy
[9] Ist Clin Humanitas IRCCS, Dept Pathol, Rozzano, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 028
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
    Sara M. Tolaney
    Sally Tan
    Hao Guo
    William Barry
    Eliezer Van Allen
    Nikhil Wagle
    Jane Brock
    Katherine Larrabee
    Cloud Paweletz
    Elena Ivanova
    Pasi Janne
    Beth Overmoyer
    John J. Wright
    Geoffrey I. Shapiro
    Eric P. Winer
    Ian E. Krop
    Investigational New Drugs, 2015, 33 : 1108 - 1114
  • [22] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.
    Means-Powell, Julie Ann
    Adjei, Alex A.
    Puzanov, Igor
    Dy, Grace K.
    Goff, Laura Williams
    Ma, Wen Wee
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Chai, Feng
    Lamar, Maria
    Schwartz, Brian E.
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Tan, Sally
    Guo, Hao
    Barry, William
    Van Allen, Eliezer
    Wagle, Nikhil
    Brock, Jane
    Larrabee, Katherine
    Paweletz, Cloud
    Ivanova, Elena
    Janne, Pasi
    Overmoyer, Beth
    Wright, John J.
    Shapiro, Geoffrey I.
    Winer, Eric P.
    Krop, Ian E.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1108 - 1114
  • [24] A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.
    Eng, Cathy
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir Ivanovich
    Langdon, Robert M.
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    Von Roemeling, Reinhard
    Schwartz, Brian E.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [26] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Eng, C.
    Bendell, J. C.
    Bessudo, A.
    Gabrail, N. Y.
    Diamond, J.
    Pande, A. U.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [27] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
  • [28] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Loupakis, F.
    Cremolini, C.
    Perrone, G.
    Stasi, I.
    Salvatore, L.
    Vincenzi, B.
    Ruzzo, A.
    Ronzoni, M.
    Bencardino, K.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
    He Wen-zhuo
    Xia Liang-ping
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03):
12345